Submit manuscript...
Advances in
eISSN: 2377-4290

Ophthalmology & Visual System

Opinion Volume 15 Issue 2

Allergy: a new approach to etiopathogenesis and treatment

Rudkovska Oksana

Department of Ophthalmology, Bukovinian State Medical University, Ukraine

Correspondence: Rudkovska Oksana, Department of Ophthalmology, Bukovinian State Medical University, Ukraine

Received: April 27, 2025 | Published: May 8, 2025

Citation: Rudkovska O. Allergy: a new approach to etiopathogenesis and treatment. Adv Ophthalmol Vis Syst. 2025;15(2):27-29. DOI: 10.15406/aovs.2025.15.00480

Download PDF

Summary

Allergy is considered to be a multifactorial disease with no known trigger. The hypothesis of allergy: in genetically predisposed individuals, long-term negative factors (chronic stress) cause excessive pupil constriction via the cortico-nuclear pathways, which is manifested by significant activation of the parasympathetic nervous system. Constricted pupils (reduced luminous flux) trigger pathological biochemical processes in the body through the optic-vegetative system, which leads to a deterioration in the physical and psychological conditions of patients.

It is proposed to include in the protocol for the treatment of allergies (and all somatic and mental illnesses) the medical dilation of the pupils to relieve the negative effects of an over-activated parasympathetic nervous system on the body.

Keywords: allergy, pupil, optic-vegetative system, parasympathetic nervous system, mydriatic

Introduction

Allergy is a hyperreaction of the immune system to stimuli, a multifactorial disease with a hereditary predisposition.1–5 However, the trigger of the disease is unknown, so treatment is symptomatic (a number of drugs- glucocorticosteroids, monoclonal antibodies-have serious side effects); allergy is characterized by chronicity, recurrence, and often resistance to anti-allergic drugs, and there are idiopathic (non-immunological) forms of the disease.6–14

Immune system irritants can include: food, pollen, dust mites, insect bites, medications, chemicals, infections, smoking, cold, heat, physical and psycho-emotional overload.2,4,15,16

Allergies affect 40% of the world's population and this number is constantly growing.17,14 Allergic diseases are among the three disorders that need to be controlled in the 21st century.5

In our opinion, the main reason for the rise in allergic diseases is chronic stress.

What can be a trigger of the allergic process?

We think it's excessively constricted pupils.

It is known that "all diseases come from the nerves". The above-mentioned negative factors cause chronic stress in genetically predisposed individuals, which causes excessive pupil constriction via the cortico-nuclear pathways.

Narrowed pupils (reduced light flux) trigger pathological biochemical processes in the body through the optic-vegetative system, which leads to a deterioration in the physical and psychological conditions of patients.

Where there is a "weak link" in the body (which is genetically programmed), it "breaks" (i.e., the pathological process is realized). In case of allergies, the target organs can be the skin, eyes, nose, lungs, etc.

Indeed, everything in the human body is interconnected. The eye is an important part of the optic-vegetative system: eye - hypothalamus - pituitary gland. Due to the stimulating effect of light, the body's endocrine glands produce hormones: pituitary, adrenal, thyroid, sex, and others. That is, the eyes provide not only vision, but also the harmonious development of all organs and systems of the body.

If the body - through the cerebral cortex, hypothalamus, reticular formation - acts on the size of the pupil, then, according to the principle of "direct feedback," the size of the pupil also affects the entire body.

When the pupil is dilated, the mood is high, the person is active physically and intellectually; when the pupil is constricted, the mood, physical and intellectual activity are reduced.18–20

Thus, in case of allergy due to chronic stress, excessive pupil constriction occurs, and the parasympathetic nervous system is significantly activated. This is manifested in symptoms such as lacrimation, rhinorrhea, itching, urticaria, cough, bronchospasm, laryngospasm, nausea, vomiting, diarrhea, etc. There are also changes in the psyche: patients are indecisive, anxious, depressed.3,12–14,21–24

Summarizing the above, we can say that the allergic process (and its idiopathic forms) is triggered by excessively constricted pupils.

The following facts support this hypothesis.

  1. A cause-and-effect relationship between ocular allergy and senile cataracts, keratoconus, and dry eye disease has been identified.25–28 We have substantiated that these diseases (cataract, keratoconus, dry eye) occur in genetically predisposed eyes with excessively constricted pupils.29–31
  2. It has been proven that global warming causes an increase in all diseases, including allergic diseases.32We have substantiated that the trigger for the multisystemic impact of heat on human health is excessively constricted pupils.33
  3. It has been established that allergies often affect the psychoemotional state of patients (anxiety, depression, inattention, hyperactivity, etc).3,14,22 We have shown that the trigger for depression and other mental illnesses is excessively constricted pupils.18–20
  4. It has been shown that allergy sufferers often have such comorbidities as hypertension, diabetes mellitus, and obesity.3,4,9,12,14,15,33 We have substantiated that the trigger for these diseases is excessively constricted pupils.34

What do we offer?

Moderately dilate the pupils in patients with allergies.

This can be done in the following ways:

  1. Midriatic eye drops. Pharmacologists need to develop a new class of these drugs that moderately dilate the pupil, act for a long time and, preferably, have a minimal effect on accommodation. It is advisable to carry out such therapy under the control of biomarkers of the activity of the parasympathetic and sympathetic nervous systems.
  2. Activation of the sympathetic nervous system: sports, limited use of gadgets, communication with family and friends, adequate sleep, positive emotions, etc. People who believe in God and do good deeds have a better prognosis.

In case of pollinosis, the use of mydriatic agents can be seasonal, in combination with the wearing of sunglasses (which also moderately dilate the pupils).

I would like to say something about anaphylactic shock (characterized by excessive pupil constriction and extreme excitation of the parasympathetic nervous system).

Unsurprisingly, it is treated with immediate intramuscular or intravenous injections of epinephrine (a sympathomimetic that dilates the pupil).7,9 However, the dose of epinephrine administered is not always sufficient to achieve mydriasis (refractory anaphylaxis).23

Therefore, we suggest that in case of anaphylaxis, in conjunction with the existing treatment protocol, immediately drop mydriatic in the eyes to dilate the patient's pupils, activate the sympathetic nervous system and relieve the negative effects of the parasympathetic nervous system on the body.35

In our opinion, this pathogenetic treatment minimizes the need for the use of glucocorticosteroids and other potent drugs.

Thus, we believe that allergic diseases are encoded in pupil size. The pupil is the most important structural element of the body. Thus, the trigger for allergies can be excessively constricted pupils and treatment should begin with their medication dilation.

Conclusions

The trigger of allergy may be excessively constricted (due to chronic stress) pupils, which is manifested by significant activation of the parasympathetic nervous system with deterioration of the physical and psychological conditions of patients.

It is proposed to include in the protocol for the treatment of allergies (and all somatic and mental illnesses) the medical dilation of the pupils to relieve the negative effects of an over-activated parasympathetic nervous system on the body.

Acknowledgments

None.

Conflicts of interest

The authors declare that there are no conflicts of interest.

Funding

None.

References

  1. Genuneit J, Standl M. Epidemiology of allergy: natural course and risk factors of allergic diseases. Handb Exp Pharmacol. 2022;268:21–27.
  2. Koidl L, Untersmayr E. The clinical implications of the microbiome in the development of allergy diseases. Expert Rev Clin Immunol. 2021;17(2):115–126.
  3. Lee EY, Copaescu AM, Trubiano JA, et al. Drug allergy in women. J Allergy Clin Immunol Pract. 2023;11(12):3615–3623.
  4. Murray CS, Jackson DJ, Teaque WG. Prevention and outpatient treatment of asthma exacerbations in children. J Allergy Clin Immunol Pract. 2021;9(7):2567–2576.
  5. Wang J, Zhou Y, Zhang H, et al. Pathogenesis of allergic diseases and implications for therapeutic interventions. Signal Transduct Target Ther. 2023;8(1):138.
  6. Amison RT, Page CP. Novel pharmacological therapies for the treatment of bronchial asthma. Minerva Med. 2022;113(1):31–50.
  7. Bilo MB, Martini M, Tontini C, et al. Anaphylaxis. Eur Ann Allergy Clin Immunol. 2021;53(1):4–17.
  8. Cloutier MM, Dixon AE, Krishnan JA, et al. Managing asthma in adolescents and adults: 2020 asthma guideline update from the National Asthma Education and Prevention Program. JAMA. 2020;324(22):2301–2317.
  9. Dribin TE, Motosue MS, Campbell RL. Overview of allergy and anaphylaxis. Emerg Med Clin North Am. 2022;40(1):1–17.
  10. Gonzalez de Olano D, Cain WV, Bernstein JA, et al. Disease spectrum of anaphylaxis disorders. J Allergy Clin Immunol Pract. 2023;11(7):1989–1996.
  11. Gouel Cheron A, Neukirch C, Kantor E, et al. Clinical reasoning in anaphylactic shock: addressing the challenges faced by anesthesiologists in real time: a clinical review and management algorithms. Eur J Anaesthesiol. 2021;38(11):1158–1167.
  12. Hammad H, Lambrecht BN. The basic immunology of asthma. Cell. 2021;184(6):1469–1485.
  13. Reddel HK, Bacharier LB, Bateman ED, et al. Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. Eur Respir J. 2021;59(1):2102730.
  14. Zhou X, Zhang P, Tan H, et al. Progress in diagnosis and treatment of difficult-to-treat asthma in children. Ther Adv Respir Dis. 2023;17:17534666231213637.
  15. Mikhail I, Stukus DR, Prince BT. Fatal anaphylaxis: epidemiology and risk factors. Curr Allergy Asthma Rep. 2021;21(4):28.
  16. Motosue MS, Li JT, Campbell RL. Anaphylaxis: epidemiology and differential diagnosis. Immunol Allergy Clin North Am. 2022;42(1):13–25.
  17. Motosue MS, Li JT, Campbell RL. Anaphylaxis: epidemiology and differential diagnosis. Immunol Allergy Clin North Am. 2022;42(1):13–25.
  18. Rudkovska OD. Depression: a new look at etiopathogenesis and treatment. J Psychol Clin Psychiatry. 2022;13(3):71–72.
  19. Rudkovska OD. Alzheimer’s disease: is there a way out of the dead end? J Psychol Clin Psychiatry. 2023;14(5):136–137.
  20. Rudkovska OD. Autism: a new approach to etiopathogenesis and treatment. J Psychol Clin Psychiatry. 2025;16(2):62–63.
  21. Baker JA. 2022 Year in Review: Pediatric Asthma. Respir Care. 2023;68(10):1430–1437.
  22. Cibircaite A, Budnaitiene V, Hansted E, et al. Assessment in children with mild to moderate bronchial asthma. Medicina (Kaunas). 2024;60(5):771.
  23. Krishnaswamy G. Critical care management of the patient with anaphylaxis: a concise definitive review. Crit Care Med. 2021;49(5):838–857.
  24. Mandlik DS, Mandlik SK. New perspectives in bronchial asthma: pathological, immunological alterations, biological targets, and pharmacotherapy. Immunopharmacol Immunotoxicol. 2020;42(6):521–544.
  25. Ahuja P, Dadachanji Z, Shetty R, et al. Relevance of IgE, allergy and eye rubbing in the pathogenesis and management of Keratoconus. Indian J Ophthalmol. 2020;68(10):2067–2074.
  26. Leonardi A, Modugno RL, Salami E. Allergy and dry eye disease. Ocul Immunol Inflamm. 2021;29(6):1168–1176.
  27. Wajnstajn D, Solomon A. Vernal keratoconjunctivitis and keratoconus. Curr Opin Allergy Clin Immunol. 2021;21(5):507–514.
  28. Yuan W, Li X, Wang G, et al. Association of autoimmune and allergic diseases with senile cataract: a bidirectional two-sample Mendelian randomization study. Front Immunol. 2024;15:1325868.
  29. Rudkovska OD. Weakness of accommodation is a trigger for eye diseases. Saarbrucken, Germany: LAP LAMBERT Academic Publishing; 2017.
  30. Rudkovska OD. Dry eye syndrome: a new look at etiopathogenesis and treatment. MOJ Clin Med Case Rep. 2021;11(3):85–86.
  31. Rudkovska OD. New concept of etiopathogenesis and treatment of keratoconus (analytical study). Adv Ophthalmol Vis Syst. 2024;14(1):44–46.
  32. Pacheco SE, Guidos-Fogelbach G, Annesi Maesano I, et al. Climate change and global issues in allergy and immunology. J Allergy Clin Immunol. 2021;148(6):1366–1377.
  33. Rudkovska OD. An approach to the prevention of global warming impact on human health. Adv Ophthalmol Vis Syst. 2024;14(3):78–79.
  34. Rudkovska OD. Global epidemics: a new look at etiopathogenesis and treatment. Adv Ophthalmol Vis Syst. 2023;13(3):90–91.
  35. Teoh L, Chang AB. Bird’s eye overview of asthma in children. Indian J Med Res. 2021;154(1):8–11.
Creative Commons Attribution License

©2025 Rudkovska. This is an open access article distributed under the terms of the, which permits unrestricted use, distribution, and build upon your work non-commercially.